Product Description: ERG240 is an oral active branched-chain amino acid aminotransferase 1 (BCAT1) inhibitor. ERG240 can be used for the research of cancer, rheumatoid arthritis, and bone disease[1].
Applications: COVID-19-immunoregulation
Formula: C7H11NaO3
References: [1]Papathanassiu, et al. Methods for treatment of cancer, inflammatory autoimmune disorders and bone diseases using branched-chain amino acid aminotransferase-1 (BCAT1) inhibitors. Patent. WO2012173987./[2]Papathanassiu AE, et al. BCAT1 controls metabolic reprogramming in activated human macrophages and is associated with inflammatory diseases. Nat Commun. 2017 Jul 12;8:16040./[3]Papathanassiu A E, et al. Inhibition of BCAT1 suppresses the expression of pro-metastatic proteins and reduces cancer metastasis[J]. Cancer Research, 2014, 74(19_Supplement): 2683-2683.
CAS Number: 1415683-79-2
Molecular Weight: 166.15
Compound Purity: 98.0
Research Area: Cancer; Inflammation/Immunology
Solubility: DMSO : 100 mg/mL (ultrasonic)/H2O : 100 mg/mL (ultrasonic)
Target: Others
Deutsch
English
